Compare CVNA & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVNA | ZTS |
|---|---|---|
| Founded | 2012 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.9B | 49.7B |
| IPO Year | 2017 | 2012 |
| Metric | CVNA | ZTS |
|---|---|---|
| Price | $397.31 | $87.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 12 |
| Target Price | ★ $439.67 | $154.18 |
| AVG Volume (30 Days) | 2.5M | ★ 4.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | ★ 431.45 | 10.05 |
| EPS | ★ 8.45 | 6.02 |
| Revenue | ★ $20,322,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | $34.66 | $5.63 |
| Revenue Next Year | $23.38 | $4.77 |
| P/E Ratio | $47.19 | ★ $14.43 |
| Revenue Growth | ★ 48.63 | 2.28 |
| 52 Week Low | $267.18 | $85.31 |
| 52 Week High | $486.89 | $172.23 |
| Indicator | CVNA | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 15.38 |
| Support Level | $390.87 | N/A |
| Resistance Level | $411.27 | $129.32 |
| Average True Range (ATR) | 19.49 | 3.08 |
| MACD | -2.80 | -2.20 |
| Stochastic Oscillator | 59.93 | 4.08 |
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.